In cirrhotic patients, dosing reduction is recommended (see DOSAGE AND ADMINISTRATION). Patients should be instructed to take supplemental calcium and morphine sulf D, if daily dietary intake is inadequate. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), pimozide (Orap), or thioridazine (Mellaril); dexamethasone (Decadron, Hexadrol); erythromycin (E-Mycin, E.E.S., Ery-Tab, Erythrocin); itraconazole (Sporanox), morphine (Nizoral); ritonavir (Norvir); rifampin (Rifadin, Rimactane, Rifater); antibiotics such as capreomycin (Capastat), rifampin (Rifadin, Rimactane, Rifater), vancomycin (Vancocin, Vancoled); a calcium channel blocker such as diltiazem (Tiazac, Cartia, Cardizem) or verapamil (Calan, Covera, Isoptin, Verelan); or The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug-metabolizing enzymes. The trial was conducted in 487 patients diagnosed with epilepsy (6 to 83 years of age) who had 1 or 2 well-documented seizures during the 3-month retrospective baseline phase who then entered the study and received morphine 25 mg/day for 7 days in an open-label fashion. Therefore, it is important to prevent pregnancy while taking this medication. In short-term (12 weeks duration or less) placebo-controlled clinical trials (3342 patients treated with SEROQUEL and 1490 treated with placebo), the percent of patients who had a fasting blood glucose ? 126 mg/dl or a non fasting blood glucose ? 200 mg/dl was 3.5% for morphine sulf and 2.1% for placebo. The other patient took 2.85 g of Effexor XR. The elimination of morphine and/or the major metabolites of morphine may be reduced by impaired renal function (see PRECAUTIONS: Renal Impairment). LIPITOR also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1. The treatment groups receiving 5 or 10 mg cyclic MORPHINE (days 15- 28) plus daily conjugated estrogens showed a significantly lower rate of hyperplasia as compared to the conjugated estrogens only group.